Skip to content
Screener

aTyr Pharma ATYR Short-Term Investments

Short-Term Investments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.35B+134%
Merck & Co. logo
Merck & Co.MRK
$292M-52.5%
United Therapeutics logo
United TherapeuticsUTHR
$859.1M-41.0%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$210.05M-2.8%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$225.54M+46.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$221.17M-38.3%

Other financials

Income statement

See full
Revenue-
Operating income-$10.9M+46.4%
Net income-$10.3M+47.2%
EPS (diluted)-$0.11+50.0%

Balance sheet

See full
Cash & equivalents$16.2M-6.2%
Total debt$11.8M-10.7%
Total equity$48.8M-34.8%
Total assets$69.8M-31.2%

Cash flow

See full
Operating cash flow-$9.4M+32.7%
CapEx$73.0K+711%
Free cash flow-$9.4M+32.2%

Valuation

See full
Market cap$50.14M-89.6%
Enterprise value$45.8M-90.4%

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-98.4%+18.0pp
Debt / equity0.2×+0.1×
Current ratio5.1×-0.5×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001339970-26-000053
Line itemJune 30, 2026December 31, 2025
Assets
Current assets:
Cash and cash equivalents$16,160$10,743
Available-for-sale investments41,25867,944
Other receivables426873
Prepaid expenses518677
Total current assets58,36280,237
Restricted cash1,4952,235

Item 1. Financial Statements

FAQ

What is aTyr Pharma's short-term investments?
aTyr Pharma (ATYR) reported short-term investments of $41.26M in Q2 2026.
How has aTyr Pharma's short-term investments changed year-over-year?
aTyr Pharma's short-term investments decreased by 34.6% year-over-year, from $63.13M to $41.26M.
What is the long-term trend for aTyr Pharma's short-term investments?
Over 5 years (2020 to 2025), aTyr Pharma's short-term investments has grown at a 35.8% compound annual growth rate (CAGR), from $14.74M to $67.94M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Ask your AI about aTyr Pharma's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude